
News|Videos|November 16, 2023
Exploring Treatment Strategies for Lymphoma: CAR T-Cell, Tafasitamab, and Clinical Trials
Author(s)Matthew A. Lunning, DO, FACP
An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















